IO Biotech Stock (NASDAQ:IOBT)


RevenueOwnershipFinancialsChart

Previous Close

$0.77

52W Range

$0.66 - $2.10

50D Avg

$0.99

200D Avg

$1.26

Market Cap

$58.61M

Avg Vol (3M)

$347.79K

Beta

0.42

Div Yield

-

IOBT Company Profile


IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DK

Employees

74

IPO Date

Nov 05, 2021

Website

IOBT Performance


IOBT Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-91.44M$-71.42M$-41.23M
Net Income$-86.08M$-71.46M$-67.88M
EBITDA$-91.44M$-70.01M$-67.77M
Basic EPS-$-2.48$-15.66
Diluted EPS-$-2.48$-15.66

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
STOKStoke Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
ERASErasca, Inc.
PMVPPMV Pharmaceuticals, Inc.
IVAInventiva S.A.
IKNAIkena Oncology, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
MNOVMediciNova, Inc.
CSBRChampions Oncology, Inc.
GPCRStructure Therapeutics Inc.
HOWLWerewolf Therapeutics, Inc.
PEPGPepGen Inc.
CMPXCompass Therapeutics, Inc.
STTKShattuck Labs, Inc.
PHVSPharvaris N.V.
NAMSNewAmsterdam Pharma Company N.V.
LYRALyra Therapeutics, Inc.